Peripheral Vascular Diseases
📧 Sign up to get email alerts when something new happens for Peripheral Vascular Diseases.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-18EMA Authorised: Brilique (ticagrelor) — AstraZeneca AB
Brilique (ticagrelor) has been authorised for use in the European Union for indications related to Acute Coronary Syndrome and peripheral va…
-
EMA approval · 2026-02-05EMA Authorised: Clopidogrel Zentiva (previously Clopidogrel Winthrop) (clopidogrel) — Zentiva k.s.
The European Medicines Agency authorised Zentiva’s generic clopidogrel product for prevention of stroke, myocardial infarction, acute corona…
-
CLINICAL_TRIALS withdrawal · 2025-04-10Clinical Trial Update: Mind Body Program for Vascular Disease [NA]
The Mind Body Program for Vascular Disease trial (NCT05757752) has been withdrawn.
-
CLINICAL_TRIALS other · 2025-02-14Clinical Trial Update: Heat Therapy and Peripheral Artery Disease [NA]
Clinical trial update showing a heat therapy study for peripheral arterial disease that is not yet recruiting.
-
CLINICAL_TRIALS trial_result · 2024-04-10Clinical Trial Update: Does Neuromuscular Electrical Stimulation Improve the Absolute Walking Distance in Patients With Intermittent Claudication Compared to Best Available Treatment? [NA]
Clinical trial assessing whether neuromuscular electrical stimulation improves absolute walking distance in intermittent claudication compar…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-03-28Clinical Trial Update: Real World Registry Assessing the Clinical Use of the Bard UltraScore Forced Focus PTA Balloon
Clinical trial update for a real-world registry evaluating Bard UltraScore Forced Focus PTA Balloon in peripheral arterial disease; study co…
-
EMA approval · 2024-02-29EMA Authorised: Clopidogrel Teva (hydrogen sulphate) (clopidogrel (as hydrogen sulfate)) — Teva Pharma B.V.
EMA authorised Clopidogrel Teva (hydrogen sulphate) for multiple cardiovascular indications including acute coronary syndrome, myocardial in…
-
EMA approval · 2023-12-19EMA Authorised: Clopidogrel Taw Pharma (previously Clopidogrel Mylan) (clopidogrel hydrochloride) — Taw Pharma (Ireland) Limited
EMA authorised a clopidogrel product (clopidogrel hydrochloride) by Taw Pharma (Ireland) Limited for peripheral vascular diseases, stroke, m…
-
CLINICAL_TRIALS trial_result · 2021-09-02Clinical Trial Update: TEsting for Arterial Disease in Diabetes (TrEAD) Study
A completed clinical trial investigating arterial disease in diabetes (TrEAD) with results posted in 2021.
-
CLINICAL_TRIALS trial_result · 2021-06-10Clinical Trial Update: Drug Eluting Balloon Angioplasty Versus Nitinol Stent Implantation in the Superficial Femoral Artery [Phase 4]
Phase 4 trial comparing drug-eluting balloon angioplasty with nitinol stent implantation in the superficial femoral artery for peripheral ar…
-
EMA withdrawal · 2021-01-25EMA Withdrawn: Clopidogrel ratiopharm GmbH (clopidogrel) — Archie Samiel s.r.o.
EMA withdrew clopidogrel from Archie Samiel s.r.o.'s product line, with therapeutic areas including peripheral vascular diseases, acute coro…
-
CLINICAL_TRIALS trial_result · 2020-05-22Clinical Trial Update: Real-World Registry Assessing the Clinical Use of the Lutonix 035 Drug Coated Balloon Catheter [NA]
Real-world registry study summary for the Lutonix 035 drug-coated balloon catheter in peripheral arterial disease shows completed results po…
-
EMA approval · 2020-03-11EMA Authorised: Clopidogrel BGR (previously Zylagren) (clopidogrel (as hydrogen sulfate)) — Biogaran
European Medicines Agency authorised Clopidogrel BGR (clopidogrel as hydrogen sulfate) by Biogaran for peripheral vascular diseases, stroke,…
-
CLINICAL_TRIALS trial_result · 2020-02-20Clinical Trial Update: Cysteinyl Leukotriene Antagonist in Atherosclerosis Inhibition in Patients After Endovascular Treatment Due to Peripheral Arterial Disease [Phase 3]
Phase 3 trial update on a cysteinyl leukotriene antagonist aiming to inhibit atherosclerosis after endovascular treatment in peripheral arte…
-
EMA approval · 2018-08-01EMA Authorised: Clopidogrel HCS (clopidogrel (as hydrochloride)) — HCS bvba
The EMA authorised Clopidogrel HCS (clopidogrel hydrochloride) for several cardiovascular indications including peripheral vascular diseases…
-
EMA withdrawal · 2018-01-04EMA Withdrawn: Clopidogrel Acino (clopidogrel) — Acino AG
Clopidogrel Acino has been withdrawn from the European market.
-
EMA withdrawal · 2017-10-24EMA Withdrawn: Clopidogrel Teva Pharma (previously Clopidogrel HCS) (clopidogrel (as hydrochloride)) — Teva B.V.
EMA withdrew Clopidogrel Teva Pharma (clopidogrel hydrochloride) from the market.
-
CLINICAL_TRIALS trial_result · 2016-02-29Clinical Trial Update: Epidemiology of Venous Disease
This update summarizes results from a completed NHLBI-sponsored study on the epidemiology of venous disease. It covers cardiovascular and pe…
-
EMA withdrawal · 2015-07-10EMA Withdrawn: Clopidogrel DURA (clopidogrel (as hydrochloride)) — Mylan dura GmbH
The EMA has withdrawn Clopidogrel DURA (clopidogrel hydrochloride) from the market for peripheral vascular diseases, stroke, and myocardial …
-
EMA withdrawal · 2015-02-03EMA Withdrawn: Clopidogrel Teva Pharma B.V. (clopidogrel (as hydrobromide)) — Teva Pharma B.V.
The EMA withdrew clopidogrel Teva Pharma B.V. (clopidogrel as hydrobromide) from marketing.
-
CLINICAL_TRIALS trial_result · 2014-09-17Clinical Trial Update: Telcagepant (MK-0974) Treatment of Migraine in Participants With Stable Vascular Disease (MK-0974-034) [Phase 3]
Phase 3 trial update for telcagepant (MK-0974) evaluating treatment of migraine in participants with stable vascular disease; study complete…
-
EMA withdrawal · 2014-09-08EMA Withdrawn: Clopidogrel Qualimed (clopidogrel (as hydrochloride)) — Qualimed
EMA withdrew Clopidogrel Qualimed (clopidogrel hydrochloride) from the market.
-
EMA withdrawal · 2014-05-12EMA Lapsed: Clopidogrel Teva Generics B.V. (clopidogrel (as hydrochloride)) — Teva Pharma B.V.
EMA has lapsed the marketing authorization for Clopidogrel Teva Generics B.V. (clopidogrel as hydrochloride).
-
EMA withdrawal · 2013-12-12EMA Withdrawn: Clopidogrel ratiopharm (clopidogrel) — Archie Samuel s.r.o.
Withdrawn clopidogrel product (Clopidogrel ratiopharm) listed by EMA; therapeutic areas include peripheral vascular diseases, stroke, and my…
-
EMA withdrawal · 2013-04-22EMA Withdrawn: Possia (ticagrelor) — AstraZeneca AB
Possia (ticagrelor) has been withdrawn from market authorization by AstraZeneca AB.